NEW TEST

Click for Pricing

Infliximab and Antibodies to Infliximab Quantitation

3016779, IFX PAN

Specimen Requirements:	
Patient Preparation:	Collect specimen before next scheduled dose of infliximab or infliximab biosimilar (trough specimen). Avoid exposure to biotin (vitamin B7) for 12 hours prior to specimen collection.
Collect:	Serum separator tube.
Specimen Preparation:	Separate serum from cells ASAP. Transfer 1 mL serum to an ARUP standard transport tube. (Min 0.1 mL)
Transport Temperature:	Refrigerated.
Unacceptable Conditions:	Grossly hemolyzed, icteric, or lipemic specimens.
Remarks:	
Stability:	After separation from cells: Ambient: 2 days; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles).
Methodology:	Quantitative Electrochemiluminescence Immunoassay (ECLIA) with Acid Dissociation
Performed:	Sun-Sat
Reported:	3-7 days
Note:	
CPT Codes:	80230; 82397
New York DOH Approval Status:	Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.

Interpretive Data:

Infliximab Quantitation:

Results of 0.5 ug/mL or higher indicate the detection of infliximab or an infliximab biosimilar. Therapeutic level may vary depending on the disease being treated.

Antibodies to Infliximab Quantitation:

Results of 20 ng/mL or higher indicate the detection of antibodies against infliximab or an infliximab biosimilar. Interpret in the context of infliximab or infliximab biosimilar trough

concentration to determine clinical significance and impact on treatment efficacy.

Reference Interval:

Test Number	Components	Reference Interval
	Infliximab Quantitation	0.5 ug/mL or greater
	Antibodies to Infliximab Quantitation	19 ng/mL or less

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.